For the quarter ending 2025-06-30, RSLS made $1,242K in revenue. -$2,630K in net income. Net profit margin of -211.76%.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 1,242 | 1,113 | 1,621* | 2,292 |
| Cost of revenue | 643 | 432 | 423* | 853 |
| Gross profit | 599 | 681 | 1,198* | 1,439 |
| Sales and marketing | 583 | 529 | 1,053* | - |
| Research and development | 476 | 364 | 606* | 399 |
| Impairment of long-lived assets | - | - | 9* | - |
| General and administrative | 1,591 | 1,627 | 630* | 2,082 |
| Selling, general and administrative expense | - | - | - | 719 |
| Transaction costs | 711 | 367 | 256* | - |
| Total operating expenses | 3,361 | 2,887 | 2,553* | 3,200 |
| Operating loss | -2,762 | -2,206 | -1,355* | -1,761 |
| Other income, net | 60 | 54 | -59* | 109 |
| Interest (income) expense, net | 18 | -40 | 2* | - |
| Loss on extinguishment of debt | - | 24 | -858* | - |
| (gain) loss on foreign currency exchange, net | 61 | -12 | -102* | 50 |
| Loss (gain) on changes in fair value of liability warrants | -1 | -3,661 | -14* | -27 |
| Loss before income tax provision | -2,622 | 1,481 | -2,358* | -1,575 |
| Income tax expense | 8 | 7 | 8* | 6 |
| Net income (loss) available to common stockholders, basic | - | - | - | -1,581 |
| Net loss | -2,630 | 1,474 | -2,366 | - |
| Basic EPS | -2.25 | 18.98 | -4.589 | -3.11 |
| Diluted EPS | -2.25 | 18.98 | -4.589 | -3.11 |
| Basic Average Shares | 1,168,759 | 77,668 | 515,566* | 508,851 |
| Diluted Average Shares | 1,168,759 | 77,668 | 515,566* | 508,851 |
ReShape Lifesciences Inc. (RSLS)
ReShape Lifesciences Inc. (RSLS)